• WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Fighting prostate cancer with groundbreaking new technique

    Groundbreaking laboratory-grown prostate cancer cells could change the way research is carried out. They will significantly increase the speed at which new drugs can be trialed.
    Cancer laboratory
    New prostate cancer models should drive research forward.
    Aside from skin cancer, prostate cancer is the most common cancer in the United States, with around 164,000 new cases each year.

    Although modern treatments, including radiotherapy and surgery, are often successful when the disease is caught early, there is still much to learn.

    For instance, some cases recur and multiple treatments are often needed. Current drugs can be effective, but cancer cells evolve so quickly that there is an ongoing arms race.

    New and innovative anticancer agents are needed, but the development of such drugs is relatively slow.

    Read full article at: https://www.medicalnewstoday.com/articles/322592.php

  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Lymphoma News Today Sent This Out to be Shared

    Rich’s RP-323 Shows Activity Against Hodgkin’s Lymphoma in Phase 1 Trial

    Experimental therapy RP-323 has shown anticancer activity against Hodgkin’s lymphoma in a Phase 1 trial. Its developer, Rich Pharmaceuticals, is now planning to evaluate the therapy in human clinical trials for the disease.

    “We look forward to being able to commence clinical trials in the future to prove that using RP-323 alone or in combination with other anticancer agents will have significant therapeutic activity against Hodgkin’s lymphoma,” Ben Chang, CEO of Rich Pharmaceuticals, said in a press release.

    RP-323 is a natural molecule isolated and purified from croton oil, which is obtained from the seeds of the purging croton, a plant native to Southeast Asia.

    The investigative therapy not only modulates cancer cell behavior, including their survival and growth, but it also promotes immune cell proliferation. This suggests it could work as an immunotherapy to boost the immune system. Given its broad effect, RP-323 represents an attractive option to target cancer.

    A Phase 1 study (NCT00004058) evaluated the anticancer potential of ascending doses of RP-323 in patients with relapsed or refractory blood malignancies or bone marrow disorders.

    The trial, led by Roger Strair, MD and PhD, oncologist at The Cancer Institute of New Jersey, included 35 patients. Participants received RP-323 infusions for five days over two consecutive weeks, followed by a two-week resting period before another treatment cycle.

    Only one patient — with relapsed or refractory Hodgkin’s lymphoma with a chest wall lesion — responded to the treatment. After three weeks of treatment with a 0.063 mg/m2 dose, the tumor had reduced from 7 cm to 2.5 cm in size. However, the tumor mass increased in size later on and treatment was stopped.

    “A phase 1 clinical trial conducted at The Cancer Institute of New Jersey [has] shown that RP-323 treatment reduced a palpable tumor mass after three weeks in a patient with Hodgkin’s lymphoma,” Chang said.

    While the patient relapsed in the trial, researchers believe the therapy candidate may have potential for Hodgkin’s lymphoma, supporting Phase 2 clinical studies.

    Results from the trial were published in the journal Cancer Chemotherapy and Pharmacology, in the study “A Phase I clinical trial with 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed refractory malignancies.”

    Rich Pharmaceuticals has also tested RP-323’s safety and efficacy in patients with relapsed or refractory acute myeloid leukemia and myelodysplatic syndrome — a group of blood disorders where immature blood cells never reach a fully mature state.


  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Seattle Genetics Starts Phase 1 Trial Testing SGN-CD48A in Relapsed or Refractory Myeloma

    Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered to the trial’s first patient, the company announced.

    The multicenter open-label trial (NCT03379584) will assess the safety and escalating doses of SGN-CD48A in roughly 75 patients with relapsed or refractory multiple myeloma who have received previous therapy with at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

    SGN-CD48A, developed by Seattle Genetics, is an antibody-drug conjugate (ADC), a new treatment strategy that combines anticancer drugs with selective targeting for cancer cells. In this case, SGN-CD48A targets a protein called CD48 whose levels are elevated at the surface of multiple myeloma cells.

    Designed to be highly stable in blood circulation, SGN-CD48A releases an anticancer therapy called monomethyl auristatin E (MMAE) into CD48-expressing cells.

    The clinical trial of SGN-CD48A will be conducted in two phases — a dose escalation part followed by a dose expansion phase.

    In the first part, patients will receive increasing doses of the therapy to determine its safety. After the first dose is deemed safe, a second group of patients will receive the next higher dose. This will continue until the maximum tolerated dose level is reached. A higher dose will only be administered once the lower doses have been shown to be safe.

    In the dose expansion phase, researchers will be evaluating the safety, tolerability, and anti-tumor activity of up to two dose levels of SGN-CD48A that were shown to be safe.

    SGN-CD48 is administered intravenously, directly into the bloodstream, every three weeks.

    The trial’s primary goal is to assess the safety and tolerability of the treatment and identify its maximum tolerated dose. Secondary endpoints will assess the therapy’s anti-tumor activity and identify the optimal single dose and regimen.

    “Multiple myeloma is the second most common blood cancer in the U.S. and remains an incurable disease despite recent medical advances,” Robert Lechleider, MD, senior vice president of clinical development at Seattle Genetics, said in a press release. “Patients are in need of new targeted treatment options that increase durable remissions.”

    “SGN-CD48A uses our latest ADC [antibody-drug conjugate] technology, and the initiation of this phase 1 trial in relapsed or refractory multiple myeloma highlights our continued leadership in ADCs as we address this challenging disease,” Lechleider added.

    Patients who may want to enroll or know more about the trial can contact Terri Parker at Yale Cancer Center, the study’s principal investigator, by email at [email redacted] or by calling[phone number redacted]. Or visit the clinical trial’s website here.

  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    I Treated Breast Cancer for Years as a Doctor. Then I Was Diagnosed

    I was a cancer expert long before I was a patient: in control, passionate about my work and invulnerable. Yet all of this would change with one phone call.
    It was a morning like many before. While discussing a complicated case with a colleague, my cell phone began to vibrate. Seeing the familiar number from the university’s radiology department, I knew it would be a “finding of concern.” With a pang of sadness, I pondered which of my patients I would soon be calling with bad news.

    The voice on the other end of the line sounded cheerful and upbeat. She told me that they had found five little “irregularities”—likely nothing of concern; I just needed to follow up and do more tests. Feeling distracted, I asked her to repeat which patient she was referring to. There was a pause on the other end, before she said, "This is about your recent mammogram." I’d missed that she hadn’t begun the conversation with, “Good morning doctor, this is about…”, but instead had called me by my first name. I should have realized then that this call was not about a patient; it was meant for me.
    Nothing prepared me for that sickening sense of foreboding and the guttural fear that gripped me that day. I was not ready for breast cancer.

    REad Full Article from Time Health >> http://new.time.com/4949983/breast-cancer-diagnosis/

    • LiveWithCancer's Avatar

      This is an excellent article. Thanks for sharing!

      almost 2 years ago
    • Journey's Avatar

      Like what LiveWithCancer says, it is an excellent article. Thanks for sharing!

      almost 2 years ago
  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    National Cancer Institute: Sitting is connected to 9 types of cancer

    More sitting down means a higher chance of getting cancer, according to new research at the National Cancer Institute


  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Why The Trauma of Cancer Doesn't End After Treatment

    ‘When you have cancer, it’s like you’re auditioning for the part of yourself and you’ve forgotten all the words.’ When you think of cancer recovery, chances are you think of someone bouncing back into great shape and health. After all, you’d assume that the worst would be over. But surviving doesn’t always mean living well. This is something that Adam Golder knows all too well. After being diagnosed with testicular cancer in 2015, the 25-year-old says his body and mind were completely devastated by the treatment. ‘In three weeks, I had aged 60 years,’ Adam old Metro.co.uk. ‘There wasn’t one part of me that wasn’t worse off than before. ‘I found the infamous “chemo-brain” the most disconcerting. I’d already felt what it was like to be physically weak or immobile but this was altogether worse. ‘It felt like I had become a burden to family and friends and as if I wasn’t an active participant anymore. It felt like I was the sick man of my friendship group.’ Adam remembers the physical aspect of recovery as just as traumatic as the mental effects. ‘Skinny, pale skinned and hairless,’ he says. ‘It wasn’t long before that was all I saw. There wasn’t a part of me that wasn’t affected. ‘I had fallen asleep a healthy man and it was as if I had woken up in the body of a different person I didn’t recognise.’ Adam isn’t alone. A recent report from Macmillan, Am I Meant To Be Okay Now? Stories of Life After Treatment, found that the health and social care system fails to support many recovering cancer patients with the ‘significant physical and emotional trauma’ the illness leaves behind. It warned that many people felt like they had ‘fallen off a cliff and don’t know what to expect or where to turn to for help’. The report found that over 80% of cancer patients who reported physical difficulties in the two years after treatment said they lacked full support to get their lives back on track. Key statistics from Macmillan/YouGov online survey of 2,067 people living with cancer in the UK. 34% are still struggling with their physical wellbeing up to two years after treatment ends 30% who have completed treatment in the last two years say their emotional wellbeing is still affected 40% who have finished treatment in the last two years are living with moderate or extreme pain or discomfort. 80% of people facing physical difficulties in the two years after treatment say they have not been fully supported to get their life back on track Fieldwork conducted 23 June to 6 July 2017. Lynda Thomas, chief executive of Macmillan Cancer Support, says: ‘It is tragic that so many people are left struggling after their cancer treatment ends. Life is often profoundly different after the rollercoaster of diagnosis and treatment ends, with people contending with serious physical and emotional issues.’ ‘The health and care system has a long way to go in terms of fully supporting people after cancer treatment. The NHS must ensure that every single person who is treated for cancer gets the support that is right for them – far too many cancer patients are badly being let down in their time of need.’ When 69-year-old Sue was diagnosed with head and neck cancer in 2016, she says she was left to deal with deep and despairing depression about the future. ‘The all clear often doesn’t herald the start of a bright new life,’ Sue tells us. ‘Rather a future of fear and anxiety about all the “what ifs”.’ A year after treatment, Sue is still struggling to cope. ‘In your head, you think it’s all over again because you’ve beaten the cancer, so you think you can be yourself,’ she explains. ‘The old you. ‘But what I didn’t take into consideration was the damage because of the treatment.’ She says this was exacerbated by her family’s expectations: ‘They were expecting me to get better now I was free of cancer. There I was trying to put on a brave face, not succeeding in my head. All it was did was reinforce that I wasn’t this strong person I was expected to be.’ (Picture: Ella Byworth for Metro.co.uk) Sue is learning to contend with this new ‘normal’, adjusting to life changes that include difficulty tasting food. ‘I ended up tears in a pub a couple of months ago because there were all these normal people around laughing and joking while I struggled to eat a bowl of soup which tasted vile,’ Sue remembers. 66-year-old Alan, who was diagnosed with bowel cancer, tells us he experienced ‘minimal support’ at the end of treatment. ‘No-one is there to advise you, no-one is there to tell you what to look out for,’ Alan tells us. ‘At the end you’re at your worst. ‘There was no guidance from the hospital on what to do next. There is very little place to turn to.’ Alan was fortunate that his local cancer support group offered free services such as acupuncture, reiki, reflexology, and counselling to as well as events with guest speakers. His experience of finding support was fairly unusual, and few others are lucky enough to access similar treatment. As Sue was putting on a brave face, healthcare professionals did not pick up on her isolation. These feelings were compounded by guilt as she admits she didn’t want to be ungrateful for being cancer-free. Sue explains that while the system works well when treating the disease, there isn’t anyone there ‘for the mental state at the end of treatment’, particularly when it comes to isolation. ‘That’s the way they think of it – we fixed you,’ says Sue. ‘You survived. ‘But they don’t know that the person that’s left isn’t the person you knew before.’ (Picture: Ella Byworth for Metro.co.uk) Sue was ultimately diagnosed with PTSD but only after she had struggled for months with a ‘dreadful sense of hopelessness’. She says there should be a package to help people. ‘Not everyone may need it, but they should be counselled when they come to the end of the physical treatment.’ The difficulty with the lack of physical and emotional support is something 32-year-old Florencia knows all too well. The single mother was diagnosed with osteosarcoma bone cancer in July 2014, and has had to contend with physical and emotional trauma years after treatment. ‘People think you’re OK after treatment and that you’re cured, but it’s not like that,’ Florencia explains. ‘The support network you have during treatment goes away because people think you’re okay after that treatment. All the challenges that come with survival persist. ‘Yes, I survived but I’m paying a high price for it. I have a prosthetic leg, hearing problems and chemotherapy brain. I also have recurring nightmares about relapsing.’ This isolation was further compounded by financial struggles. Florencia lost her job after treatments left her so drained she was unable to go back to waitressing at a hotel. This was particularly concerning for her as her seven-year-old son has autism and she receives no financial support from anyone else. Although an assessment occupational therapist notified her that she was unable to work on her feet anymore, her agency didn’t offer her a telephone or receptionist job on the basis that her English wasn’t good enough. ‘I was only offering housekeeping jobs and that was more physical than the restaurant so I couldn’t do it,’ says Florencia. (Picture: Ella Byworth for Metro.co.uk) Although Florencia was later offered a job processing applications, it brought its own issues: ‘The more I worked, the more I paid childcare. And as the job was admin-heavy, I had to keep on working past my hours but wasn’t paid for it.’ It eventually led to a nervous breakdown: ‘The babysitter kept ringing, asking when I’d be finished and saying she couldn’t cope with his challenging behaviour. My son was upset because I wasn’t there and I couldn’t even get a lunch break. It was making me sick. ‘If I continue, I’m going to relapse of cancer. I had enough. ‘I felt badly let down by everyone. I went to job with best intentions, actively looking for work but it was an impossible situation.’ What should people with cancer know about recovery? What should people with cancer know about recovery? It’s easy to get caught up thinking that this is the end but there’s lots cancer survivors can do post treatment, says Dany Bell, Macmillan Cancer Support’s specialist advisor on Treatment and Recovery. Understand what you can do to help yourself through physical activity – even if that’s increasing the amount of walking. Know where you can manage anxiety. It doesn’t necessarily have to be face-to-face. You can download a mindfulness app and work through it. Everybody is different and different things will work for different people You may run into problems even two years down the line with fatigue or anxiety about cancer coming back. People need to know that’s okay and normal and that there is help out there and they don’t have to be alone Talk it through with a good friend or a GP who can signpost to further resources Don’t let it go on for years – seek help sooner rather than later Many of the people I spoke to questioned whether they should have gone through treatment at all. For Florencia in particular, having to contend with side effects and financial instability has led her to believe she can’t move on.

    Read more: http://metro.co.uk/2017/11/21/why-the-trauma-of-cancer-doesnt-end-after-treatment-7094279/?utm_sq=fo4sr64nce?ito=cbshare

    Twitter: https://twitter.com/MetroUK | Facebook: https://www.facebook.com/MetroUK/

  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    Health Tip of the Day

    Position computer monitor 20 to 30 inches from your eyes. The top of the screen should be at or below eye level and keep the screen clean to reduce eye strain.

    • beachbum5817's Avatar

      I had never heard this before now. So, I got out my tape measure to see how I was doing. I actually have it correct. That's a first! As always, thanks for teaching me something new.

      about 2 years ago
    • papabill's Avatar

      I am with DawnRisisng, after measuring the distance it works best at about 15-16 inches for easiest reading. But, I do agree the screen should be just be below eye-level and clean at all times to maximize easiest readings. Keep the faith.

      about 2 years ago
    • Paperpusher's Avatar

      I had to check. Mine is at eye level and I tend to sit about 2 feet away. I did change the font size for my eyes. Dawn Rising, you might want to consider that.

      about 2 years ago
  • WhatNextEmails' Avatar

    WhatNextEmails posted an update

    We are requesting tips from everyone for the newly diagnosed on what to do, what to expect, maybe some things they might not see coming, and things that you wished you had been told when you were diagnosed. When you see the question posted on the questions page asking for your tips for newly diagnosed, we would certainly appreciate your feedback.

    We are putting together a Tips For The Newly Diagnosed page, your helpful, inspirational, or motivational tips might be included on our new page. We thank you in advance for your participation!


    • BuckeyeShelby's Avatar

      I kept a small notebook w/me at all times. I wrote down questions for my surgeon and for my medical oncologist to make sure I got answers. If you're going for chemo, make sure you have loose sleeves, if going w/IV or wear something w/ready access to the port. I agree w/taking a blanket and snacks/light lunch, especially if you're going to be there more than a couple hours -- mine was between 6 & 7. I always had something to keep me busy, whether waiting for a dr's appt or in chemo -- for me it was books & my smart phone. Whether chemo or radiation, communicate w/your techs or nurses. My 1st chemo, I had an allergic reaction -- wasn't sure if I was going to pass out or barf (didn't do either), but I squeaked for help and was soon surrounded but pretty much every chemo nurse on site.

      about 2 years ago
    • Danfan714's Avatar

      Keep a journal of all of your Dr appointments. That way you know what they said, you can refer to it, and you can write down the questions that you have for each. I date each one. Still do it after 5 years.

      about 2 years ago
    • abrub's Avatar

      Mention EVERY side effect, no matter how small or seemingly insignificant. They will adjust your chemo accordingly, and the side effects give the drs important information. You may have to simply plow through, or they may be able to modify your treatment or suggest ways of dealing with effects that will not negatively affect your outcome.

      about 2 years ago